Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL)

NCT04240808 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Non Hodgkin Lymphoma

Interventions

BIOLOGICAL: UCD19 CAR T Cells

Sponsor

University of Colorado, Denver